ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...
Mare BioInnovations launchd Ocythera led by Dr. Martin Petkovich with support of Dr. Don Cameron and acting CEO Joseph ...
US Oncologists anticipate rapid biosimilar uptake - up to 50% of PD-1/PD-L1 eligible patients within the first year - while ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
MONTREAL and TORONTO and VANCOUVER, BC, Jan. 15, 2026 /CNW/ – adMare BioInnovations is proud to announce the creation of ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
ANKTIVA, in combination with an immune checkpoint inhibitor, has received accelerated approval from the Saudi Food and Drug ...
Explore key identity management challenges in pharma and biotech SaaS platforms and learn practical solutions for security, ...
Detailed price information for Revolution Medicines Inc (RVMD-Q) from The Globe and Mail including charting and trades.
Sahil Verma [email protected] For the first time in the history of Ladakh after attaining the status of a Union Territory ...
VIVUS LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs, ...
AstraZeneca’s $80 billion revenue target for 2030 is “very much within reach,” Chief Fin | While the $80 billion revenue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback